Investors need to read the Real Money commentary regarding Bristol Myers to get a real read on the stock, said TheStreet’s Jim Cramer. Earlier this month, the New York City-based pharmaceutical company’s lung cancer drug Opdivo failed in a late-stage clinical trial. AVEO Pharmaceuticals recently announced that it will work with Bristol-Myers on a clinical evaluation of its tivozanib drug in combination with Bristol-Myers’ Opdivo drug. It will supply the Opdivo drug for use in a Phase I/II AVEO trial. The combination drug will be given to patients with advanced renal cell carcinoma.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
